Doximity/$DOCS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Doximity
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
Ticker
$DOCS
Sector
Primary listing
NYSE
Industry
Health Care Technology
Headquarters
Employees
830
ISIN
US26622P1075
Website
Doximity Metrics
BasicAdvanced
$11B
54.42
$1.11
1.41
-
Price and volume
Market cap
$11B
Beta
1.41
52-week high
$85.21
52-week low
$25.00
Average daily volume
2.9M
Financial strength
Current ratio
6.967
Quick ratio
6.729
Long term debt to equity
0.941
Total debt to equity
1.145
Profitability
EBITDA (TTM)
241.443
Gross margin (TTM)
90.20%
Net profit margin (TTM)
39.13%
Operating margin (TTM)
40.46%
Effective tax rate (TTM)
15.32%
Revenue per employee (TTM)
$690,000
Management effectiveness
Return on assets (TTM)
12.31%
Return on equity (TTM)
22.50%
Valuation
Price to earnings (TTM)
54.423
Price to revenue (TTM)
19.788
Price to book
10.54
Price to tangible book (TTM)
11.48
Price to free cash flow (TTM)
42.315
Free cash flow yield (TTM)
2.36%
Free cash flow per share (TTM)
142.76%
Growth
Revenue change (TTM)
19.98%
Earnings per share change (TTM)
54.17%
3-year revenue growth (CAGR)
18.41%
3-year earnings per share growth (CAGR)
16.61%
What the Analysts think about Doximity
Analyst ratings (Buy, Hold, Sell) for Doximity stock.
Bulls say / Bears say
Doximity's new self-service advertising platform is expected to expand its addressable market by attracting smaller pharmaceutical brands and healthcare organizations, potentially driving incremental revenue growth. (Investing.com)
The company's recent Q3 fiscal 2025 results showed a 25% year-over-year revenue increase to $168.6 million, surpassing consensus estimates and indicating strong financial performance. (Benzinga)
Analysts have raised their price targets for Doximity, with Barclays upgrading the stock to Overweight and increasing the price target to $52, reflecting optimism about the company's growth prospects. (Investing.com)
Doximity's heavy reliance on pharmaceutical advertising revenue poses a risk, as any reduction in pharmaceutical ad budgets could significantly impact the company's financial performance. (Investing.com)
An ongoing investigation into potential breaches of fiduciary duty by Doximity's directors and officers may negatively affect investor confidence and the company's stock price. (Monexa)
Some analysts have expressed concerns about Doximity's high valuation, with the stock trading at 40.5 times forward EBITDA, which may not be sustainable if growth slows. (Monexa)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Doximity Financial Performance
Revenues and expenses
Doximity Earnings Performance
Company profitability
Doximity News
AllArticlesVideos
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
GlobeNewsWire·2 weeks ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
GlobeNewsWire·3 weeks ago
The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks
24/7 Wall Street·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Doximity stock?
Doximity (DOCS) has a market cap of $11B as of June 28, 2025.
What is the P/E ratio for Doximity stock?
The price to earnings (P/E) ratio for Doximity (DOCS) stock is 54.42 as of June 28, 2025.
Does Doximity stock pay dividends?
No, Doximity (DOCS) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Doximity dividend payment date?
Doximity (DOCS) stock does not pay dividends to its shareholders.
What is the beta indicator for Doximity?
Doximity (DOCS) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.